MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Adaptive Biotechnologies Corporation DSO Ratio 2011-2026 | ADPT
Annual DSO Ratio Adaptive Biotechnologies Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60.7 | 81.3 | 83.6 | 56.6 | 32.5 | 42.2 | 54.4 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 83.6 | 32.5 | 58.7 |
Quarterly DSO Ratio Adaptive Biotechnologies Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.3 | 68.1 | 74.2 | - | 75.1 | 82 | 87.2 | - | 75.5 | 58.3 | 86.1 | - | 25.3 | 23.5 | 47.2 | - | 36.2 | 40.2 | 35.4 | - | 34.9 | 43.7 | 49.6 | - | 44.4 | 52.2 | 63 | - | 25.5 | 19 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 87.2 | 19 | 51.7 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
115 | $ 20.41 | -1.4 % | $ 2.57 B |  USA |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.84 | - | $ 4.58 M |  China |
 |
Axsome Therapeutics
AXSM
|
105 | $ 164.26 | -1.27 % | $ 8.17 B | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.69 | -3.4 % | $ 1.1 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
31.9 | $ 25.63 | -4.59 % | $ 686 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
32.9 | $ 1.01 | -0.98 % | $ 74.1 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
4.13 | $ 3.22 | -3.59 % | $ 1.15 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Agios Pharmaceuticals
AGIO
|
47.4 | $ 28.11 | -3.73 % | $ 1.63 B | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Фармсинтез
LIFE
|
209 | - | - | - |  Russia |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
94.5 | $ 3.67 | -3.42 % | $ 116 M |  France |
 |
Altimmune
ALT
|
15.1 K | $ 4.08 | -1.92 % | $ 290 M | USA |
 |
Teligent, Inc.
TLGT
|
90.7 | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
169 | - | - | $ 2.91 B | USA |
 |
Amarin Corporation plc
AMRN
|
213 | $ 13.79 | -1.01 % | $ 5.72 B |  Irlanda |
 |
AbbVie
ABBV
|
258 | $ 233.58 | -0.27 % | $ 413 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
42.5 | - | - | $ 8.14 B | USA |
 |
AIM ImmunoTech
AIM
|
46 | $ 0.75 | -4.39 % | $ 36.1 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
27.3 | $ 35.09 | -2.45 % | $ 3.64 B | USA |